Bio-Rad Laboratories, Inc. research snapshot
BIO AI stock analysis currently views Bio-Rad Laboratories as a durable laboratory tools and diagnostics business whose quality is stronger than its recent organic growth. The latest public close was $296.11 on July 10, 2026, and market-cap math using 26.76 million shares gives about $7.92 billion. FY2025 revenue was $2.583 billion, free cash flow was about $375 million, and Q1 2026 revenue grew 1.1% on a reported basis, although currency-neutral sales declined 4.2%. Reported earnings are noisy because the Sartorius AG investment can create large gains or losses unrelated to Bio-Rad operating performance. The BIO AI stock forecast therefore uses ranges and operating conditions, not a certain price prediction.
Current price
$296.11 at the July 10, 2026 close
Market cap
About $7.92 billion using 26.76 million shares; the July 9 reported market cap was $7.96 billion
AI score
57 / 100
Rating
Quality diagnostics and life science franchise with recurring consumables, slow organic growth, and material Sartorius mark-to-market exposure
Trend status
Price is modestly above the 50-day and 200-day averages, while RSI is near neutral
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bio-Rad sells instruments, reagents, consumables, software, and quality controls to research laboratories, biopharma manufacturers, hospitals, and diagnostic laboratories. Clinical diagnostics is about 60% of 2025 sales and is the steadier part of the mix. | High |
| Moat | The moat comes from validated workflows, installed instruments, recurring reagents and controls, product breadth, regulatory know-how, and customer service. Switching costs are stronger in clinical workflows than in academic research tools, where budgets and product cycles are more exposed. | Medium-high |
| Management | CEO Norman Schwartz and the team continued share repurchases, completed the Stilla Technologies acquisition, and focused the diagnostics portfolio in 2025. The next test is whether capital allocation can restore organic growth while protecting margins and avoiding overreliance on financial-asset gains. | Medium |
| Financial trend | Revenue recovered slightly to $2.583 billion in 2025, but operating income fell to $47.2 million after a $172.8 million impairment. Q1 2026 reported sales rose 1.1%, non-GAAP operating income was $39.3 million, and free cash flow was $78.1 million. | High |
| Valuation | At $296.11, TTM GAAP PE was about 47.45x because the earnings base is distorted by investment gains and losses. TTM FCF per share of $13.21 implies about 22.42x FCF and a 4.46% FCF yield, which is more useful but still assumes recovery in the operating business. | Medium |
| Technical trend | The July 9 technical snapshot showed price above the 50-day average of $283.25 and just above the 200-day average of $294.10. RSI of 54.61 and average volume of 313,176 shares indicate neither strong momentum nor a confirmed breakdown. | Medium-high |
| Risk level | Risk is medium-high because Sartorius valuation moves can dominate GAAP earnings, research funding remains weak, currency affects reported sales, China reimbursement is pressured, and Bio-Rad carries debt, acquisition, restructuring, and execution risk. | High |
| AI confidence | The descriptive data are well supported, but AI cannot reliably forecast Sartorius share prices, laboratory budgets, currency moves, activist outcomes, or the timing of a margin recovery. | High data confidence |
| Investment certainty | Investment certainty is medium because the business has tangible recurring demand, while the growth rate, margin path, and valuation support are not yet strong enough for high certainty. | Medium |
BIO AI stock forecast
The BIO AI stock forecast is scenario-based rather than a point target. A three-year calculation using FY2025 non-GAAP EPS of $9.92, growth assumptions of 10%, 2%, and negative 5%, and target multiples of 35x, 30x, and 24x produced reference values of about $462, $316, and $204. Those are model outputs, not promises, and the ranges below are deliberately wider.
$360 to $460
More likely if academic and biotech funding recover, currency-neutral sales return to growth, Clinical Diagnostics keeps recurring consumables demand, gross margin improves, Stilla adds useful digital PCR growth, and the Sartorius stake remains supportive without distracting from operations.
$275 to $335
More likely if 2026 revenue stays near management guidance of negative 3.0% to positive 0.5% currency-neutral growth, operating margin remains within the updated 10.0% to 12.0% outlook, and investors value the company on normalized cash flow rather than volatile GAAP earnings.
$200 to $270
More likely if research budgets stay weak, diagnostics reimbursement or China demand deteriorates, gross margin continues to fall, the Sartorius position declines, restructuring or acquisition costs rise, or the market compresses the multiple assigned to slow-growth laboratory tools.
BIO AI technical analysis
BIO AI technical analysis uses the latest public snapshot available by the July 12, 2026 cutoff. The latest close was $296.11 on July 10. StockAnalysis technical statistics were last updated for the July 9 close and showed a 50-day average of $283.25, a 200-day average of $294.10, RSI of 54.61, beta of 1.09, and 20-day average volume of 313,176 shares. This static page does not fetch request-time data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $296.11 | Public closing quote on July 10, 2026. Refresh the live quote before using any level. |
| Near support | $294.10 | Reported 200-day moving average at the July 9 snapshot. A sustained loss would weaken the long-term chart position. |
| Deeper support | $283.25 | Reported 50-day moving average at the July 9 snapshot. Moving averages change daily and require a live check. |
| Near resistance | $302 to $320 | The recent $302.16 high and the $320 top analyst target are reference areas, not guaranteed targets. |
| Moving averages | 50-day $283.25; 200-day $294.10 | The July 10 close was modestly above both averages, but the margin was small relative to normal price movement. |
| Momentum | RSI 54.61 | Momentum was close to neutral in the dated snapshot, so price and volume confirmation matter more than an RSI signal alone. |
| Volume | 20-day average 313,176 shares | A move through resistance is more credible when volume expands and the accompanying company thesis is unchanged. |
| Volatility | 5-year beta 1.09 | The beta is near the market average, but Sartorius valuation changes and earnings releases can create company-specific gaps. |
| Invalidation | Decisive close below the live 50-day average | For a trend-following framework, a confirmed break below the live 50-day average near $283.25 weakens the setup. It is not a personal sell instruction. |
BIO AI trading strategy
The BIO AI trading strategy is a rules-based research framework, not personalized advice. It combines price and volume confirmation with currency-neutral sales, segment trends, gross margin, operating margin, free cash flow, Sartorius exposure, research funding, diagnostics reimbursement, China demand, and capital allocation.
Wait for BIO to hold above the live 200-day and 50-day averages and for a move through the $302 to $320 reference area to show volume confirmation. Check the next earnings release and Sartorius exposure before treating a breakout as fundamental confirmation.
Define risk before entry. A failed breakout or decisive close below the live 50-day average near $283.25 invalidates this chart setup.
If BIO pulls back toward the moving averages without a negative operating update, compare the price with normalized FCF, Clinical Diagnostics growth, Life Science funding conditions, margin guidance, debt, and the value of the Sartorius position.
Do not average down solely because the price fell. The setup fails if weaker sales, lower margins, a Sartorius decline, or a capital-allocation problem arrives with the pullback.
Track currency-neutral revenue by segment, recurring quality-control and consumables sales, gross margin, operating margin, free cash flow, share repurchases, Stilla integration, China reimbursement, research funding, debt, and the Sartorius stake value.
Refresh the forecast after earnings, a material Sartorius move, an acquisition or restructuring announcement, a change in guidance, or a sustained break of the chart levels. Avoid stale technical data around those events.
Investment research summary
Bio-Rad supplies the tools that let researchers measure biology and clinical laboratories deliver standardized test results. Customers pay for reliable instruments, validated workflows, reagents, consumables, quality controls, and service rather than for a single isolated product.
The strongest moat is the installed base in clinical diagnostics, where laboratories standardize workflows and continue buying test kits and controls. Life Science has technical breadth and brand credibility, but academic budgets and biopharma funding make that side more cyclical. The moat is useful if Bio-Rad keeps products compatible, regulated, and economically valuable.
The thesis can fail if academic funding stays depressed, diagnostics reimbursement worsens, competitors win validated workflows, currency reduces reported revenue, China demand weakens, acquisitions do not earn their cost, or the Sartorius stake falls enough to obscure or weaken financial flexibility. The most important accounting risk is mistaking investment gains for operating earnings.
Management has used cash for share repurchases and acquisitions while keeping a large strategic stake in Sartorius. The capital-allocation test is whether buybacks, Stilla integration, product investment, and portfolio cleanup improve per-share operating cash flow without sacrificing resilience. CEO continuity helps, but the next margin and growth decisions matter more than a management narrative.
Life science research, molecular testing, biopharma manufacturing, and clinical diagnostics remain long-term growth areas, supported by biological complexity and the need for reproducible measurement. Near-term spending is not a straight line. Bio-Rad sits in the enabling-tools layer, so it benefits from industry progress but still depends on laboratory budgets, reimbursement, regulation, and procurement cycles.
At roughly $7.92 billion of market value, BIO is not cheap on TTM GAAP earnings because the reported earnings base is distorted. The more useful reference is about 22.42x TTM FCF, but that still assumes the business can stabilize margins and convert installed-base demand into cash. A margin of safety requires a conservative view of organic growth, normalized FCF, Sartorius volatility, and the cost of future acquisitions.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BIO price and market capitalization | $296.11 close on July 10, 2026; 26.76 million shares outstanding; calculated market cap about $7.92 billion. The July 9 reported market cap of $7.96 billion differed by 0.45% in financial_rigor.py. | StockAnalysis price history and statistics, ChartExchange share count, and financial_rigor.py | July 12, 2026 |
| FY2025 revenue and segment mix | $2.583 billion total revenue, including $1.021 billion Life Science and $1.562 billion Clinical Diagnostics. Revenue was up 0.7% reported, while currency-neutral sales were essentially flat. | Bio-Rad FY2025 results and 2025 Form 10-K | July 12, 2026 |
| FY2025 earnings and free cash flow | GAAP net income was $759.9 million, heavily affected by a $900.4 million gain from changes in the fair value of equity securities. Non-GAAP net income was $270.5 million and free cash flow was about $375 million. | Bio-Rad FY2025 results and SEC 2025 Form 10-K | July 12, 2026 |
| Q1 2026 operating results | $592.1 million revenue, $34.1 million GAAP operating income, $50.9 million non-GAAP net income, and $78.1 million free cash flow. Reported revenue grew 1.1%, while currency-neutral revenue declined 4.2%. | Bio-Rad Q1 2026 financial results | July 12, 2026 |
| Liquidity and debt | At March 31, 2026, cash and cash equivalents were $507.2 million, short-term investments were $1.0575 billion, and current plus long-term debt was about $1.2034 billion. The resulting cash plus short-term investments less debt was about $361 million before other liabilities and other investments. | Bio-Rad Q1 2026 balance sheet | July 12, 2026 |
| 2026 outlook | Management updated 2026 non-GAAP currency-neutral revenue guidance to negative 3.0% to positive 0.5% and estimated non-GAAP operating margin guidance to 10.0% to 12.0%. | Bio-Rad Q1 2026 financial results | July 12, 2026 |
| Technical snapshot | At the July 9, 2026 close: 50-day moving average $283.25, 200-day moving average $294.10, RSI 54.61, 5-year beta 1.09, and 20-day average volume 313,176 shares. | StockAnalysis statistics | July 12, 2026 |
| Valuation reference | Using $296.11 price, TTM EPS of $6.24, book value per share near $256.00, TTM FCF per share of $13.21, and no dividend, financial_rigor.py calculated 47.45x PE, 1.16x PB, 22.42x P/FCF, and 4.46% FCF yield. | StockAnalysis financials and statistics, verified with financial_rigor.py | July 12, 2026 |
This BIO page is an informational research tool, not investment advice, a recommendation, or a guarantee of performance. Forecast ranges are scenarios based on available dated data and assumptions that can be wrong. Verify live market data and primary filings before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
